NovartisPharmaceutical Companies

ATIVESITE | Integrating ESG into Strategy | Novartis Lecture from Nov 12, 2021



ESG issues have become increasingly important for companies around the world leading to the development of strategies to improve ESG outcomes. However, many companies have struggled to achieve their objectives. For the Novartis Lecture of November 12, 2021, Professor George Serafeim, the Charles M. Williams Professor of Business Administration at Harvard Business School, discussed research over the past decade that provides guidance on what really works in ESG strategy implementation. Specifically, the lecture touched on the ideas of ESG as strategy and differentiation, the role of leadership commitment, governance and corporate culture, and achieving impact transparency and valuation through impact weighted accounts. Professor Serafeim’s presentation was followed by a fireside chat with Dr. Lutz Hegemann, Group Head Corporate Affairs and Global Health at Novartis, with both speakers answering questions submitted by the livestream audience.

Learn more about the Novartis Lecture series: https://bit.ly/3xp7MZO

©2021 Novartis AG

Source Novartis YouTube

1111

ativesite

Health First, Well-Being Always!